Inhibition of TNF activity
AssigneeApplied Research Systems ARS Holding N.V.
InventorsDan Aderka, Talma Eshed (Englender)
Life of this patent
Estimating the term…
Abstract
The bioactivity of TNF is inhibited by administering heparin or a derivative thereof along with a soluble TNF receptor. The heparin or derivative thereof can be administered simultaneously with the soluble TNF receptor, either in separate compositions or in compositions containing both heparin or a derivative thereof and at least one soluble TNF receptor. The heparin or derivative may also be administered without the soluble TNF receptor and still effect some amount of inhibition of TNF bioactivity.
Claims13
A composition for inhibiting the bioactivity of TNF, comprising an effective amount of heparin or a low molecular weight derivative thereof, or a mixture of heparin and a low molecular weight derivative thereof, and at least one sTNF-R.
A composition comprising heparin and/or a low molecular weight derivative thereof and a sTNF-R.
In a method for inhibiting the activity of TNF in a subject comprising treating said subject with an effective amount of sTNF-R, the improvement whereby the effect of sTNF-R is potentiated comprising treating said subject with a combination of said sTNF-R with an amount of heparin or a low molecular weight derivative or a mixture of heparin and a low molecular weight derivative thereof, said amount being effective to potentiated the effect of said sTNF-R.
Dependencies are inferred from the claim text.